Invention Application
- Patent Title: FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION
-
Application No.: US16789707Application Date: 2020-02-13
-
Publication No.: US20200172556A1Publication Date: 2020-06-04
- Inventor: Patrick Rene ANGIBAUD , Vineet PANDE , Barbara HERKERT , Daniel Jason KROSKY , Olivier Alexis Georges QUEROLLE , Aaron Nathaniel PATRICK
- Applicant: Janssen Pharmaceutica NV
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@645697e2 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@17995337
- Main IPC: C07D519/00
- IPC: C07D519/00 ; A61P35/02 ; A61P3/10
Abstract:
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
Public/Granted literature
- US10975100B2 Fused bicyclic inhibitors of menin-MLL interaction Public/Granted day:2021-04-13
Information query
